Furthermore, we found that inhibiting PRMT5 activity using the PRMT5 inhibitor EPZ015866 significantly reduced the levels of H3R2me1 and H3R2me2s on the ANGPT2 promoter in MYBL1-overexpression HCC cells (Fig. 6C). This evidence concerns the gene MYBL1 and hepatocellular carcinoma.